J. Najib

发表

Efficacy and Safety of Zopiclone and Eszopiclone in the Treatment of Primary and Comorbid Insomnia

J. Najib, 2010 .

Eszopiclone: Review and Clinical Applications in Chronic and Comorbid Insomnia

J. Najib, 2015 .

Pharmacologic and Pharmacokinetic Aspects Lisdexamfetamine dimesylate is a water-soluble prodrug of the single isomer—d-amphetamine and l-lysine—that remains Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder

J. Najib, Dexter Wimer, J. Zeng, 2017 .

Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.

J. Najib, 2002, Clinical therapeutics.

Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.

J. Najib, 2006, Clinical therapeutics.

Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder

Maliha Tabassum, J. Najib, Ekaterina Didenko, 2020, Current medical research and opinion.

The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.

J. Najib, 2009, Clinical therapeutics.

Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.

J Najib, J. Najib, 2001, Clinical therapeutics.

Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder

J. Najib, 2012, Adolescent health, medicine and therapeutics.

Daridorexant, an Orexin Receptor Antagonist for the Management of Insomnia.

L. Dima, J. Najib, Yuliana Toderika, 2023, American journal of therapeutics.

Revising senior pharmacy grand rounds to incorporate longitudinal board review to prepare students for licensing examination

A. Rivkin, N. Marzella, J. Najib, 2013 .

The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.

J. Najib, 2009, Clinical therapeutics.